Loading...
XASXEYE
Market cap26mUSD
Jan 08, Last price  
0.19AUD
1D
8.57%
1Q
5.56%
Jan 2017
-86.43%
Name

Nova Eye Medical Ltd

Chart & Performance

D1W1MN
XASX:EYE chart
P/E
—
P/S
1.87
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.72%
Rev. gr., 5y
7.64%
Revenues
23m
+37.00%
26,939,00034,691,00045,502,00051,181,00059,254,00048,553,00043,112,00047,503,00043,079,00054,378,00062,760,00073,015,00071,809,00079,431,00016,140,00012,769,00013,394,00013,378,00017,025,00023,325,000
Net income
-9m
L-42.52%
-1,102,0003,693,0004,267,0004,745,000-22,616,0003,820,000-710,000920,000-816,000788,0001,680,0003,027,000-894,000-5,074,000-6,661,000-6,991,000-4,356,000-7,496,000-15,293,000-8,790,000
CFO
-8m
L+15.06%
-2,961,000871,0001,931,000-1,189,0003,976,0004,689,000198,0001,837,0001,944,0002,704,0006,890,0005,216,000-3,496,000522,000-4,207,0005,452,000-12,905,000-4,683,000-6,721,000-7,733,000
Dividend
Jul 21, 20200.425 AUD/sh
Earnings
Feb 21, 2025

Profile

Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.
URL
https://www.ellex.com/
IPO date
Oct 12, 1987
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
23,325
37.00%
17,025
27.26%
13,378
-0.12%
Cost of revenue
18,515
24,186
19,408
Unusual Expense (Income)
NOPBT
4,810
(7,161)
(6,030)
NOPBT Margin
20.62%
Operating Taxes
(1,709)
(321)
Tax Rate
NOPAT
4,810
(5,452)
(5,709)
Net income
(8,790)
-42.52%
(15,293)
104.02%
(7,496)
72.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,430
7,470
BB yield
-16.54%
-17.60%
Debt
Debt current
480
639
544
Long-term debt
6,218
1,784
2,798
Deferred revenue
(966)
Other long-term liabilities
966
Net debt
547
(5,067)
(4,726)
Cash flow
Cash from operating activities
(7,733)
(6,721)
(4,683)
CAPEX
(211)
(800)
(5,591)
Cash from investing activities
(325)
(800)
(4,576)
Cash from financing activities
6,912
6,817
(402)
FCF
1,421
(2,145)
(3,642)
Balance
Cash
6,151
7,419
8,000
Long term investments
71
68
Excess cash
4,985
6,639
7,399
Stockholders' equity
21,330
23,191
30,397
Invested Capital
19,694
18,083
24,941
ROIC
25.46%
ROCE
19.49%
EV
Common stock shares outstanding
204,141
160,167
148,534
Price
0.22
-16.98%
0.27
43.24%
0.19
-42.19%
Market cap
44,911
5.81%
42,444
54.46%
27,479
-41.79%
EV
45,458
37,377
22,753
EBITDA
7,799
(4,864)
(4,219)
EV/EBITDA
5.83
Interest
70
54
64
Interest/NOPBT
1.46%